To our knowledge, this report describes one of the earliest documented pediatric cases of de novo Graves' disease emerging during prolonged GnRH agonist therapy for CPP, rigorously confirmed by a board-certified pediatric endocrinologist using diagnostic criteria consistent with current international guidelines [10,11]. The gene discussed is GNRH1; the disease is Graves disease.